Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia

Next Previous
Trial Profile

A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarilumab (Primary) ; Hydroxychloroquine; Lopinavir/ritonavir; Remdesivir; Steroids
  • Indications COVID 2019 infections; Pneumonia
  • Focus Therapeutic Use
  • Acronyms ESCAPE

Most Recent Events

  • 16 Feb 2022 Status changed to completed, as per results presented at the 29th Conference on Retroviruses and Opportunistic Infections
  • 16 Feb 2022 Primary endpoint (time to clinical improvement, defined as the time from receiving the first dose of drug to an improvement of two points (from the status at baseline) on a 7-point category ordinal scale.) has not been met, as per results presented at the 29th Conference on Retroviruses and Opportunistic Infections
  • 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top